Denali Therapeutics

DNLIleader

Denali Therapeutics is developing disease-modifying therapies for neurodegeneration (Parkinson's, ALS, Alzheimer's) using proprietary blood-brain-barrier crossing platform and LRRK2 biology.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($188M)

Datos estáticos (cargando finanzas en tiempo real…)

Collaboration Revenue (Biogen, Sanofi) (100%)

Composición de segmentos y clientes principales

Detalles del producto

LRRK2 Inhibitors (Parkinson's)40%

DNL201/DNL151 — oral LRRK2 kinase inhibitors targeting genetic Parkinson's disease, partnered with Sanofi.

Enzyme Transport Vehicle (ETV)35%

Blood-brain-barrier crossing technology enabling CNS delivery of large-molecule enzymes — licensed to multiple partners.

ALS Programs (TDP-43, RIPK1)25%

First-in-class RIPK1 inhibitor and TDP-43 programs for ALS, in Phase II with AZ collaboration.

Relaciones en la Cadena de Suministro

Socios

Biogen Inc.

ALS program collaboration

Impacto: significant

Contexto macro y de mercado

헬스케어Noticias del sector

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Próximos catalizadores

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Denali Therapeutics impulsado por IA.

Información de la Empresa

Sede Central

South San Francisco, California, USA

Fundación

2015

Empleados

700

Sitio Web

denalitherapeutics.com

Estado del sector — 헬스케어

Noticias del sector